vnrx-5024
Small moleculeexperimental
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Feb 21, 2020 (NCT04314206)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Beta lactamase TEM-1INHIBITOR
Q7B899 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT04314206 | Phase 1 | Feb 21, 2020 | National Institute of Allergy and Infectious Diseases (NIAID), VenatoRx Pharmaceuticals, Inc. |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2020 |
| VenatoRx Pharmaceuticals, Inc. | For profit | 1 | 1 | 1 | 2020 |
2 organizations
Page 1 / 1